DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 02:17:50 28/05/2024 pm IST | ||
| 396.1 EUR | -0.03% |
|
| Current month | +8.62% | ||
| 1 month | +8.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 396.1 | -0.03% |
| 27/24/27 | 396.2 | +0.40% |
| 24/24/24 | 394.7 | +0.20% |
| 23/24/23 | 393.9 | +0.26% |
| 22/24/22 | 392.9 | +0.97% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 02:17 pm IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8U |
| ISIN | DE000ME7D8U2 |
| Date issued | 23/01/2024 |
| Maturity | 20/09/2024 (115 Days) |
| Parity | 1 : 1 |
| Emission price | 373 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 396.2 € |
|---|---|
| Lowest since issue | 359.5 € |
| Spread | 0.32 € |
| Spread % | 0.08% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Certificates
- Certificat
